H E A L T H

2nd Quarter 2022 Results *August 11, 2022*

Shawn Morris – Chief Executive Officer Parth Mehrotra – President & COO David Mountcastle – Chief Financial Officer

Disclaimer

Forward-Looking Statements

This presentation contains forward-looking statements that express the Company's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results that include, but are not limited to: 2022 financial guidance and other projections and forecasts. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the Company's control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in filings with the Securities and Exchange Commission ("SEC"), including those under "Risk Factors" therein. Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements speak only as of the date made. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Use of Non-GAAP Financial Information

In order to provide investors with greater insight, promote transparency and allow for a more comprehensive understanding of the information used by management in its financial and operational decision-making, the Company supplements its condensed consolidated financial statements presented on a GAAP basis herein with certain non-GAAP financial information, including: Care Margin; Platform Contribution; Platform Contribution margin; Adjusted EBITDA; Adjusted EBITDA margin; Adjusted Net Income; and Free Cash Flow. Reconciliations of these non-GAAP measures to their most directly comparable GAAP measures are included in the financial schedules in the Appendix of this presentation, as well as in the Company's quarterly financial press releases and related Form 8-K filings with the SEC. This information can be accessed for free by visiting www.priviahealth.com or www.sec.gov.

Management has not reconciled forward-looking non-GAAP measures to its most directly comparable GAAP measure of Operating Income and Net Income. This is because the Company cannot predict with reasonable certainty and without unreasonable efforts the ultimate outcome of certain GAAP components of such reconciliations due to market-related assumptions that are not within our control as well as certain legal or advisory costs, tax costs or other costs that may arise. For these reasons, management is unable to assess the probable significance of the unavailable information, which could materially impact the amount of the future directly comparable GAAP measures.



Agenda

- Key Highlights
- Business Update
- 2Q and 1H Financial Performance
- Updated 2022 Outlook
- Q&A



2Q'22 Highlights

Operating Strength and Financial Momentum

- Continued high-level operating execution in 2Q'22
 - Practice Collections +67.6% versus 2Q'21
 - Adjusted EBITDA +54.8% versus 2Q'21
- Updated financial guidance reflects strong performance and visibility through FY'22

Growth and Expansion


- Solid same-store growth
- Strong **new provider additions** in existing markets
- **Robust pipeline** focused on new market entries

CMS' Proposed 2023 Medicare Physician Fee Schedule Rule

- Proposals are a **net positive** for Privia Health
- Significant endorsement of the Medicare Shared Savings Program
 - ✓ MSSP serves 11M patients across 525,000 providers




Leading Next Generation Physician Organization and Care Delivery Network




V|A. Note: All data as of June 30, 2022.

Diversified Value-Based Platform Across Reimbursement Models¹




2Q'22 Performance





¹ Solid bar represents government lives and shaded bar represents commercial lives. Note: Any slight variations in percentage calculations due to rounding. For reconciliations of Care Margin to Operating Income, Platform Contribution to Operating Income, and Adjusted EBITDA to Net Income, please see the Appendix.

1H'22 Performance







Note: Any slight variations in percentage calculations due to rounding. For reconciliations of Care Margin to Operating Income, Platform Contribution to Operating Income, and Adjusted EBITDA to Net Income, please see the Appendix.

Capital Resources Update

- Repaid \$33.1M term loan in June 2022 with cash on hand
- Annual cash interest expense savings of ~\$1M
- \$65M revolving loan facility remains in place, available and undrawn as of 6.30.22

(In millions)	At 6.30.22	At 12.31.21
Cash and cash equivalents	\$ 292.2	\$ 320.6
Less: Notes payable (including current portion) and debt issuance costs		<u>33.3</u>
Net cash position, total	<u>\$ 292.2</u>	<u>\$ 287.3</u>



FY'22 Guidance at August 11, 2022 *


(\$ in millions)		FY'22 Guidance at 3.22.22			Guidance at 5.12.22	Current FY'22 Guidance				
		Low	'	High				Low		High
Implemented Providers		3,625 3,725		Unchanged		Ν	/lid-to	l-to-High End		
Attributed Lives	860	860,000 890,000		Unchanged				Midp	oint	
Practice Collections	\$ 2	2,050	\$	2,200	Mid-to-High End				High	End
GAAP Revenue	\$	1,225	\$	1,300	Mid-to-High End				High	End
Care Margin	\$	280	\$	295	Mid-to-High End				High	End
Platform Contribution	\$	130	\$ 135		High End	\$		137	\$	142
Adjusted EBITDA	\$	52	\$ 56		High End	\$	5	57	\$	60

* 2022 guidance reflects only previously announced new market entries





Privia Health: Economic Model¹



Reconciliation of Operating Loss to Care Margin^{a 1}

	For the Three Months Ended June 30,				For the Six Months Ended June 30,						
(unaudited; \$ in thousands)	2022			2021		2022		2021			
Operating loss	\$	(5,250)	\$	(193,187)	\$	(16,797)	\$	(185,280)			
Depreciation and amortization		1,165		440		2,283		885			
General and administrative		33,107		168,657		69,217		182,653			
Sales and marketing		4,819		11,178		9,480		14,362			
Cost of platform	_	42,384	_	68,731		83,656	_	95,693			
Care margin	\$	76,225	\$	55,819	\$	147,839	\$	108,313			

^(a) Any slight variations in totals are due to rounding.

(1) Care Margin is total revenue less the sum of physician and practice expense.

Reconciliation of Operating Loss to Platform Contribution^{a 2}

	For the Three Months Ended June 30,					For the Six Months Ended June 30,						
(unaudited; \$ in thousands)	2022		2021			2022	2021					
Operating loss	\$	(5,250)	\$	(193,187)	\$	(16,797)	\$	(185,280)				
Depreciation and amortization		1,165		440		2,283		885				
General and administrative		33,107		168,657		69,217		182,653				
Sales and marketing		4,819		11,178		9,480		14,362				
Stock-based compensation ⁽⁵⁾	_	3,664	_	36,040		8,287		36,040				
Platform contribution	\$	37,505	\$	23,128	\$	72,470	\$	48,660				

^(a) Slight variations in totals are due to rounding.

(2) Platform Contribution is total revenue less the sum of physician and practice expense and cost of platform.

(5) Amount represents stock-based compensation expense included in Cost of Platform.

Reconciliation of Net Loss to Adjusted EBITDA^{a 3}

	For the Three Months Ended June 30,					For the Six Months Ended June 30,					
(unaudited; \$ in thousands)		2022		2021		2022	2021				
Net loss	\$	(10,475)	\$	(172,534)	\$	(27,985)	\$	(167,136)			
Stock-based compensation		18,470		202,560		43,351		202,661			
Intangible amortization expense		856		160		1,668		320			
Provision for (benefit from) income tax		5,468		(20,004)		11,776		(18,004)			
Other expenses		1,149		223		1,498		1,717			
Adjusted net income attributable to Privia Health Group, Inc.	\$	15,468	\$	10,405	\$	30,308	\$	19,558			
Adjusted net income per share attributable to Privia Health Group, Inc. stockholders – basic	\$	0.14	\$	0.10	\$	0.28	\$	0.20			
Adjusted net income per share attributable to Privia Health Group, Inc. stockholders – diluted	\$	0.13	\$	0.09	\$	0.25	\$	0.17			
Weighted average common shares outstanding – basic		108,685,835		102,739,033		108,374,181	_	99,381,053			
Weighted average common shares outstanding – diluted		122,549,934		115,727,026	_	121,942,820	_	112,505,977			

(a) Any slight variations in totals due to rounding.

(3) Adjusted EBITDA is net income (loss) attributable to Privia Health Group, Inc. shareholders and subsidiaries excluding minority interests, provision (benefit) for income taxes, interest income, interest expense, depreciation and amortization, stock-based compensation, severance charges and other non-recurring expenses. Note: Other expenses include certain non-cash or non-recurring costs.

Reconciliation of Net Loss to Adjusted Net Income Per Share ^a

	For the Three Months Ended June 30,				ŀ	for the Six Mon	ths Ei	s Ended June 30,	
(unaudited; \$ in thousands)	2022		2021			2022	2021		
Net loss	\$	(10,475)	\$	(172,534)	\$	(27,985)	\$	(167,136)	
Stock-based compensation		18,470		202,560		43,351		202,661	
Intangible amortization expense		856		160		1,668		320	
Provision for (benefit from) income tax		5,468		(20,004)		11,776		(18,004)	
Other expenses		1,149		223		1,498		1,717	
Adjusted net income attributable to Privia Health Group, Inc.	\$	15,468	\$	10,405	\$	30,308	\$	19,558	
Adjusted net income per share attributable to Privia Health Group, Inc. stockholders – basic	\$	0.14	\$	0.10	\$	0.28	\$	0.20	
Adjusted net income per share attributable to Privia Health Group, Inc. stockholders – diluted	\$	0.13	\$	0.09	\$	0.25	\$	0.17	
Weighted average common shares outstanding – basic		108,685,835		102,739,033		108,374,181		99,381,053	
Weighted average common shares outstanding – diluted		122,549,934		115,727,026	:	121,942,820		112,505,977	

^(a) Any slight variations in totals due to rounding.

PRIVIA.

Thank You

PriviaHealth.com

Contact:

Robert P. Borchert SVP, Investor & Corporate Communications robert.borchert@priviahealth.com Phone: 817.783.4841